esophageal tumor
Conditions
Interventions
non-immunotherapy group:None
Sponsors
Jiangsu Cancer Hospital(The affliated Cancer Hospital of Nanjing Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. ASA grade II to III; 2. initial gastroscopic pathology with a definitive diagnosis of esophageal squamous carcinoma; 3. receiving preoperative neoadjuvant therapy; 4. patients who underwent surgery for esophageal cancer from January 2020 to December 2023 at our institution.
Exclusion criteria
Exclusion criteria: 1. Combination of severe cardiac, pulmonary, hepatic, renal, cerebral and immune system diseases (e.g. NYHA cardiac function = grade III, FEV1%pred <50%, Child Pugh classification = grade C, blood creatinine =177umol/L, etc.); 2. combined history of other malignant tumors; 3. patients with distant metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of intraoperative hypotension;Intraoperative vasoactive drug utilization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of intraoperative hypotensive events;Intraoperative vasoactive drug dosage and type;Cardiac enzyme profile;Incidence of intraoperative hypoxemia;Incidence of pulmonary complications ;Postoperative hospitalization time;chest tube drainage time;relative counts of lymphoid subgroups;indicators of liver and kidney function (alanine aminotransferase, glutamine aminotransferase, bilirubin, albumin, creatinine, urea nitrogen, uric acid);calcitoninogen;C-reactive protein;troponin T ;N-terminal B-type natriuretic peptidogen; | — |
Countries
CHINA
Contacts
Public ContactLiu Hui
Jiangsu Cancer Hospital(The affliated Cancer Hospital of Nanjing Medical University)
Outcome results
None listed